Abstract
OBJECTIVE--To assess the financial implications of antitachycardia pacing in patients with frequent supraventricular tachycardia. PATIENTS--Intertach pacemakers were implanted in 25 patients (mean age 47 years, five men): 22 had atrioventricular nodal reentry tachycardia. The patients had failed a mean of 4.9 (range zero to eight) drugs and had been admitted to hospital 3.7 (zero to 31) times over a symptomatic period of 13.9 years (two months to 54 years). RESULTS--The mean admission time for implantation was 2.8 (two to seven) days. One patient with Wolff-Parkinson-White syndrome subsequently underwent surgery. Infection occurred in two patients, and pain over the pacemaker required its resiting in two. Two patients have had one admission each for tachycardia. Six patients remain on anti-arrhythmic drugs. Costs were calculated including value added tax, capital charges, and allocated overheads. The cost a year before pacing was 1174 pounds including drug costs, clinic visits, and hospital admissions. The mean cost of pacemaker implantation was 3364.22 pounds, including the pacemaker and lead, admission and procedure, readmissions and first pacing check. Subsequent annual follow up cost was 73.72 pounds including annual clinic visits and drug costs. The cost of pacing is 4241 pounds whereas medical management costs 7044 pounds assuming pacemaker life of six years: with a 10 year life the cost is 4537 pounds compared with 11,740 pounds: with a 12 year life the cost is 4685 pounds compared with 14,088 pounds. CONCLUSION--The excess cost of implantation of an antitachycardia pacemaker is minimal in patients with frequent supraventricular tachycardia despite drug treatment and is justified by excellent control of symptoms and reduction of drug use and hospital admissions.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cox J. L., Ferguson T. B., Jr, Lindsay B. D., Cain M. E. Perinodal cryosurgery for atrioventricular node reentry tachycardia in 23 patients. J Thorac Cardiovasc Surg. 1990 Mar;99(3):440–450. [PubMed] [Google Scholar]
- Goy J. J., Fromer M., Schlaepfer J., Kappenberger L. Clinical efficacy of radiofrequency current in the treatment of patients with atrioventricular node reentrant tachycardia. J Am Coll Cardiol. 1990 Aug;16(2):418–423. doi: 10.1016/0735-1097(90)90595-g. [DOI] [PubMed] [Google Scholar]
- Jackman W. M., Wang X. Z., Friday K. J., Roman C. A., Moulton K. P., Beckman K. J., McClelland J. H., Twidale N., Hazlitt H. A., Prior M. I. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current. N Engl J Med. 1991 Jun 6;324(23):1605–1611. doi: 10.1056/NEJM199106063242301. [DOI] [PubMed] [Google Scholar]
- Jazayeri M. R., Hempe S. L., Sra J. S., Dhala A. A., Blanck Z., Deshpande S. S., Avitall B., Krum D. P., Gilbert C. J., Akhtar M. Selective transcatheter ablation of the fast and slow pathways using radiofrequency energy in patients with atrioventricular nodal reentrant tachycardia. Circulation. 1992 Apr;85(4):1318–1328. doi: 10.1161/01.cir.85.4.1318. [DOI] [PubMed] [Google Scholar]